title: Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children.
abstract: Thirty-six children with growth hormone deficiency were treated for up to 48 months with methionyl human growth hormone (hGH) synthesised by DNA recombinant methods. The growth rate for these children increased from 3.2 +/- 1.1 cm/yr to 10.5 +/- 2.2 cm/yr (mean +/- SD). This was similar to the effect of pituitary hGH in ten GH deficient children, 3.8 +/- 1.0 to 10.1 +/- 1.1 cm/yr. Serum somatomedin C rose from 0.26 +/- 0.23 U/ml to 0.79 +/- 0.53 U/ml after 6 months of methionyl-hGH therapy, similar to the effect of pituitary hGH. The incidence of antibody formation to methionyl-hGH was higher than that observed with pituitary hGH (Kabi) but poor growth was observed only in the one patient on methionyl-hGH who acquired high-titre high-binding-capacity antibodies to hGH. No consistent changes in levels of antibodies to Escherichia coli proteins were detected. No other allergic manifestations or systemic side-effects were demonstrable.
authors.forename: S L
authors.initials: SL
authors.lastname: Kaplan
authors.forename: L E
authors.initials: LE
authors.lastname: Underwood
authors.forename: G P
authors.initials: GP
authors.lastname: August
authors.forename: J J
authors.initials: JJ
authors.lastname: Bell
authors.forename: S L
authors.initials: SL
authors.lastname: Blethen
authors.forename: R M
authors.initials: RM
authors.lastname: Blizzard
authors.forename: D R
authors.initials: DR
authors.lastname: Brown
authors.forename: T P
authors.initials: TP
authors.lastname: Foley
authors.forename: R L
authors.initials: RL
authors.lastname: Hintz
authors.forename: N J
authors.initials: NJ
authors.lastname: Hopwood
mesh_terms: D000293:Adolescent; D000365:Age Determination by Skeleton; D000906:Antibodies / Q000032:analysis; D000907:Antibodies, Bacterial / Q000032:analysis; D000917:Antibody Formation; D001426:Bacterial Proteins / Q000276:immunology; D001786:Blood Glucose / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004274:DNA, Recombinant; D004340:Drug Contamination; D004926:Escherichia coli / Q000276:immunology; D005260:Female; D006128:Growth / Q000187:drug effects; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000031:analogs & derivatives* / Q000172:deficiency* / Q000276:immunology / Q000627:therapeutic use; D019382:Human Growth Hormone; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000097:blood; D008297:Male; D008722:Methods; D011863:Radioimmunoassay; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000906:Antibodies; D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001786:Blood Glucose; D004274:DNA, Recombinant; D007074:Immunoglobulin G; D007328:Insulin; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone